Wells Fargo & Co (WFC), Baxter International Inc. (BAX): Obamacare-Inspired Investment Opportunities
Love it or hate it, the Patient Protection and Affordable Care Act -- commonly referred to as Obamacare -- changes the health care landscape.
Posts Tagged ‘Novartis A G (NVS)’
AstraZeneca plc (ADR) (AZN), Sanofi SA (ADR) (SNY): Don’t Ignore These European Healthcare Stocks
Healthcare stocks have rallied over the past couple years, and for good reason.
Sanofi SA (ADR) (SNY), Novo Nordisk A/S (ADR) (NVO), Johnson & Johnson (JNJ): Can Investors Bet on These 3 Pharma Companies?
It is expected that the death rate from diabetes will top 50% in the next ten years, which will make it a leading cause of death worldwide.
Aegerion Pharmaceuticals, Inc. (AEGR), Arena Pharmaceuticals, Inc. (ARNA): Investment Opportunities in Drug Launches
There are investment opportunities in every sector, but biotechs launching new drugs offer a unique investment opportunity to take advantage of hyper-growth as sales increase ...
Johnson & Johnson (JNJ): New Drugs and Better Manufacturing Make This Stock a Buy
Johnson & Johnson (NYSE:JNJ) stands alone as a leader across the major health-care industries.
Johnson & Johnson (JNJ): Why Might This Play Shake Up the Cancer-Drug Industry?
Medical firm Johnson & Johnson (NYSE:JNJ) recently announced a private-company acquisition that could have major implications for one of the markets in which it operates.
Idenix Pharmaceuticals Inc (IDIX), GenMark Diagnostics, Inc (GNMK): Horrendous Health-Care Stocks This Week
Shares of small biotech Idenix Pharmaceuticals Inc (NASDAQ:IDIX) took a 32% nosedive this week, following unwelcome news from the U.S. Food and Drug Administration.
Myriad Genetics, Inc. (MYGN): Big Pharma’s Intellectual Property Blues
It’s not easy being a biotech company.
Biogen Idec Inc. (BIIB), Sanofi SA (ADR) (SNY): A Must Have Pharma Stock
After a year-long dream run, Biogen Idec Inc. (NASDAQ:BIIB) lost 5.25% in the week ended Friday, June 7.
Questcor Pharmaceuticals Inc (QCOR), Avanir Pharmaceuticals, Inc. (AVNR): 3 Humongous Healthcare Stocks This Past Week
Investors in a handful of health-care stocks are probably all smiles this week. Several stocks saw nice double-digit gains over the past five days.
AstraZeneca plc (ADR) (AZN), GlaxoSmithKline plc (ADR) (GSK): A Big Pharma Company With a Juicy Dividend Yield and Low Valuation
Recently, AstraZeneca plc (ADR) (NYSE:AZN) announced that it has agreed to acquire Pearl Therapeutics, the respiratory drug manufacturer, in a transaction worth around $1.15 billion...
AstraZeneca plc (ADR) (AZN), Novartis AG (ADR) (NVS): 5 Biotech Giants with Lucrative Dividend Yields
Investing in biotech stocks is relatively risky amid the volatility of the market. There are many factors that can greatly affect share trends and price performance.
Why The Pfizer Inc. (PFE)-Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Settlement Affects the Whole Industy
Generic-drug makers are always on the hunt for the next branded drug to take down.
Valeant Pharmaceuticals Intl Inc (VRX) Biting More Than it Can Chew
While the debate goes on whether increasing output by acquiring new businesses through mergers, acquisitions and takeovers is the right way forward, the biopharmaceutical industry...
Valeant Pharmaceuticals Intl Inc (VRX): This Company is Set for Newer Heights in the Eye-Care Sector
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has been on an acquisition spree. Its latest purchase is Bausch + Lomb in an all-cash deal worth $8.7 billion.
Merck & Co., Inc. (MRK), Pfizer Inc. (PFE): Juicy Dividends From the Three Pharmaceutical Giants
Merck & Co., Inc. (NYSE:MRK) has been trying to generate more value for its shareholders via its share buyback program.
Why Questcor Pharmaceuticals Inc (QCOR) Shares Exploded Higher
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Questcor Pharmaceuticals, Inc. (QCOR) Buys Potential Rival Drug
Why try to beat 'em if you can just buy 'em? That's the approach that Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) is taking.
Celgene Corporation (CELG)’s Abraxane: A Therapy for Advanced Pancreatic Cancer?
Celgene Corporation (NASDAQ:CELG)’s Abraxane is primarily used to treat breast and lung cancer.
Merck & Co., Inc. (MRK), Clovis Oncology Inc (CLVS): All About ASCO – 2013 Highlights
Every week at The Motley Fool we reflect on the top stories in the biotech sector in a wrap-up column.
Johnson & Johnson (JNJ), VIVUS, Inc. (VVUS): The Three Biggest Risk Factors for a Stroke
Often referred to as "the silent killer," stroke is the fourth-leading cause of the death in the U.S., behind only heart disease, cancer, and chronic lower respiratory diseases...
Threshold Pharmaceuticals, Inc. (THLD), Celgene Corporation (CELG)- Tackling Cancer: Pancreatic Cancer’s Biggest Current & Upcoming Players
As I noted 12 weeks ago, cancer statistics are both staggering and disappointing.
Gilead Sciences, Inc. (GILD)’s Entry Into Cancer Therapy
It is interesting to watch a bio company change tactics and go into an area it hasn't explored before. This, to me, is like watching a child suddenly grow up.
Novartis AG (ADR) (NVS), Sanofi SA (ADR) (SNY): Pharma Big Wigs Warm Up to Africa’s $40 Billion Opportunity
For a long time, Africa’s traditional enemy with regard to diseases have been communicable diseases like HIV and Malaria. Now, however, this trend is changing.
Does Novartis AG (ADR) (NVS) Pass Buffett’s Test?
We'd all like to invest like the legendary Warren Buffett, turning thousands into millions or more.
Valeant Pharmaceuticals Intl Inc (VRX) is Expanding its Eye Care Business
The pharmaceutical industry is getting hotter with increasing M&A activities.
Novartis AG (ADR) (NVS), Alexion Pharmaceuticals, Inc. (ALXN), Celgene Corporation (CELG), Onyx Pharmaceuticals, Inc. (ONXX): 4 Companies Riding the Orphan Drug Rocket
A recent report by EvaluatePharma claims that sales of orphan drugs -- ones that target rare diseases -- will grow at twice the rate of the overall prescription market.
Johnson & Johnson (JNJ), Pfizer Inc. (PFE), Novartis AG (ADR) (NVS): Is There Growth Left in Massive Drug Stocks?
In an already massive market segment, are dividends all you can hope for when you hunt down "elephants" like Warren Buffett does? While you probably won't get a five-bagger at...
Pfizer Inc. (PFE) Stock Checkup for May
We dread some checkups. Some people even put them off. If you own Pfizer Inc. (NYSE:PFE) stock, though, there's no need for dread or delay.
Santarus, Inc. (SNTS) Is a Real Gas!
Investing in the stock market can sometimes be a gut wrenching experience. However, for investors in Santarus, Inc.
The Home Depot, Inc. (HD), BP plc (ADR) (BP) & The Five Richest Countries in the World
The recession has taken a toll on economies around the world, from driving down standards of living to sending unemployment to record levels.
Ariad Pharmaceuticals, Inc. (ARIA), Pfizer Inc. (PFE), Celgene Corporation (CELG): Who’s The Best?
Investors emphasize the "bio" in biotech a great deal. We look at how much patients' health improved in clinical trials.
Myriad Genetics, Inc. (MYGN), Roche Holding Ltd. (ROG): Angelina Jolie’s Selfless Act Heightens Breast Cancer Awareness
I admit to not being a big fan of many of her movies -- possibly the only man on the planet who will admit so -- but there's little denying that movie sensation Angelina Jolie...
3M Co (MMM), Thermo Fisher Scientific Inc. (TMO): The Hidden Opportunity of the Novel Coronavirus
According to the Center for Disease Control and Prevention, there are only five known coronaviruses that can infect humans.
Allergan, Inc. (AGN): Is It Worth Looking At?
Allergan, Inc. (NYSE:AGN) has been consistently increasing on the market since the market bottom, from nearly $32 per share in November 2008 to more than $116 per share in ...
Pfizer Inc. (PFE): Risks, Hesitations & Key Opportunities
Take a look around the pharmaceutical industry and you won't find many companies with market caps exceeding $100 billion (seven by my count).
GlaxoSmithKline plc (ADR) (GSK), Theravance Inc (THRX): Take a Deep Breath Before This Big FDA Decision
Every Sunday I make it a point to examine a combination of earnings stories or Food and Drug Administration panel reviews or PDUFA decisions in the upcoming week that you can'...
Allergan, Inc. (AGN), Regeneron Pharmaceuticals Inc (REGN), And What You Should Know
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Pfizer Inc. (PFE), Eli Lilly & Co. (LLY) & Other Names To Know: A Full Breakdown
Investing in biotech companies can be intimidating, especially for investors without a science background. But there's hope.
Who’s Suing Novartis AG (ADR) (NVS), And Why?
Would you hold a pharmaceutical product presentation in Hooters? That's just one of many alleged instances that the U.S.
Pfizer Inc. (PFE), Novartis AG (ADR) (NVS), GlaxoSmithKline plc (ADR) (GSK) & Big Pharma’s Kickback Conundrum
Big pharma is a controversial industry. Along with tobacco companies, they are some of the most vilified businesses in the world.
Intel Corporation (INTC), Vodafone Group Plc (ADR) (VOD), and Novartis AG (ADR) (NVS): Three Misunderstood Large Cap Value Finds
Perkins Large Cap Value Fund (JNPLX) looks for temporarily misunderstood companies.
Novartis AG (ADR) (NVS), Sanofi SA (ADR) (SNY), Regeneron Pharmaceuticals Inc (REGN): Three Potential Game Changers for America’s No. 1 Killer
Heart disease kills nearly 600,000 Americans every year, making it the nation's No. 1 cause of death, according to the Centers for Disease Control and Prevention.
Sanofi SA (ADR) (SNY), Johnson & Johnson (JNJ), and Investing in Potential Blockbusters
A popular drug that crosses a benchmark sale of $1 billion for the manufacturer is called a blockbuster drug.
Pfizer Inc. (PFE) & More…a ‘Breakthrough’ May Be on the Way for Breast Cancer Patients
The process of developing a drug from start to finish is incredibly arduous, usually involves around $1 billion in costs, and can take upwards of a decade to complete.
ACADIA Pharmaceuticals Inc. (ACAD), Pfizer Inc. (PFE): This Stock Is Fine, So What Just Happened to Mine?
While the Dow Jones Industrial Average (INDEXDJX:.DJI) continues to climb to new heights on little more than a central bank-induced asset levitation scheme and closing the day...
Abbott Laboratories (ABT): This Company & Ache Labs: A Perfect Match?
Abbott Laboratories (NYSE:ABT) has begun its new future swimmingly.
Pfizer Inc. (PFE): Could Novartis AG (ADR) (NVS) Decision Bring Pharma Sector Rotation?
Over the last year the biggest drug makers, like Pfizer Inc.
Biogen Idec Inc. (BIIB), Sanofi SA (ADR) (SNY), Elan Corporation, plc (ADR) (ELN): The Greatest Thing Since Sliced Bread Has Arrived for MS Patients
Last November, I examined five experimental drugs that appeared as if they had all of the tools necessary to become life-changing blockbusters from a financial and quality of ...
